BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity remains negative

Q2 FY2026 total equity was -$2.51B, compared with -$1.78B a year earlier.

Context

  • Total equity amounted to 205.9% of total assets at the end of Q2 FY2026, up 41.2 pp from a year earlier.
  • Total equity grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -40.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.51B-10.4% QoQ
Last fiscal yearDec 2025
-$2.08B-42.5% YoY
Year agoJun 2025
-$1.78B-40.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.9%——
1 year-42.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(2.08B) USD
Year-over-year change
-42.5%

Total Equity vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -40.9% is the 9th highest of 11, against a peer median of -0.8%.
  • Total equity amounts to 205.9% of total assets for BBIO, versus a peer median of 31.1%.
BBIO Competitors
Total Equity for BBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$6.26T USD+103190.9%+9.8%54.1%
ASNDAscendis Pharma A/SSep 2026€1.5B EUR+962.0%—61.8%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.35B USD+440.4%—24.4%
DNLIDenali Therapeutics Inc.Jun 2026$835.18M USD-18.7%-0.9%72.1%
IONSIonis Pharmaceuticals, Inc.Sep 2026$393.64M USD-36.3%-5.1%13.5%
MAZEMaze Therapeutics, Inc.Mar 2026$341.7M USD+17.0%+51.8%81.4%
SRRKScholar Rock Holding CorporationSep 2026$168.68M USD-31.2%-1.9%37.8%
TVTXTravere Therapeutics, Inc.Sep 2026$22.58M USD-69.3%+38.9%2.7%
PTCTPTC Therapeutics, Inc.Jun 2026-$165.36M USD+19.9%—5.1%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$229M USD-251.4%—17.7%
BBIOBridgeBio Pharma, Inc.Jun 2026-$2.51B USD-40.9%—205.9%
Peer median (excluding BBIO) —-0.8%+4.4%31.1%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents393.77M376.69M375.94M681.1M570.12M
Short-term Investments442.89M95.23M58.95M017.36M
Net Receivables19.75M17.08M1.75M4.72M139.44M
Inventory000026.75M
Other Current Assets177K37.93M27.65M3.83M0
Total Current Assets888.86M548.85M477.59M720.69M753.68M
Property, Plant & Equipment (Net)45.97M25.25M19.84M12.78M13.52M
Goodwill00000
Intangible Assets44.93M28.71M26.32M23.93M28.08M
Long-term Investments2.42M2.87M3.74M143.75M81.44M
Tax Assets00000
Other Non-current Assets30.61M17.36M18.88M18.2M(81.44M)
Total Non-current Assets123.93M74.18M68.79M198.65M41.59M
Total Assets1.01B623.04M546.38M919.34M936.03M
Account Payables11.88M11.56M10.66M9.62M36.23M
Short-term Debt000017.41M
Tax Payables00000
Deferred Revenue08.16M6.1M020.27M
Other Current Liabilities37.04M31.26M65.6M16.2M214.06M
Total Current Liabilities135.07M121.43M143.84M154.4M287.97M
Long-term Debt1.7B1.71B1.73B1.72B2.71B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000013.08M
Other Non-current Liabilities22.07M26.64M9.36M496.47M244K
Total Non-current Liabilities1.74B1.75B1.75B2.22B2.72B
Total Liabilities1.88B1.87B1.89B2.38B3.01B
Common Stock154K157K181K196K202K
Retained Earnings(1.44B)(1.92B)(2.56B)(3.1B)(3.82B)
Accumulated OCI(132K)(328K)31K8K12K
Other Stockholders Equity00000
Minority Interest4.84M9.69M11.72M10.29M(570K)
Total Equity(865.58M)(1.24B)(1.34B)(1.46B)(2.08B)
Total Debt1.73B1.72B1.74B1.73B2.73B
Net Debt1.33B1.35B1.36B1.05B2.16B

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.